Fluacizine

Fluacizine
	File:Fluacizine structure.svg
Gene therapy
Clinical data
Other names	Flouracizine, Phtorazisin, ftoracizin, 10-(3-(Diethylamino)propionyl); -2-(trifluoromethyl)phenothiazine, 2-(Trifluoromethyl)-10-; (N,N-diethyl-beta-alanyl)phenothiazine
Routes of; administration	Oral, intramuscular
Physiological data
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Identifiers
	IUPAC name 3-diethylamino-1-[2-(trifluoromethyl) phenothiazin-10-yl]-propan-1-one;
CAS Number	30223-48-4;
PubChem Template:Abbreviation	161562;
Chemical and physical data
Formula	C20H21F3N2OS
Molar mass	394.455 g/mol
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCC(=O)N1C2=CC=CC; =C2SC3=C1C=C(C=C3)C(F)(F)F;

Fluacizine (INN) is an antidepressant with sedative properties derived from phenothiazine.

Fluacizine possesses strong central and peripheral anticholinergic activity.

Uses

Fluacizine is indicated in bipolar depression, the emotional problems accompanying schizophrenia, anxiety accompanying depression, and for the depressive and extrapyramidal symptoms resulting from neuroleptic therapy. It is not effective for atypical depression or late-onset depression (once known as involutional melancholia).

Side effects of fluacizine include feeling of weakness, nausea, and dry mouth.

Fluacizine is contraindicated in patients with liver or kidney impairment, enlarged prostate, peptic ulcer or who have taken MAOIs less than 14 days before starting therapy. la:Fluacizinum Template:WikiDoc Sources